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Investigating Effects of Ananadmide Treatment on Zebrafish Embryonic Development

In recent years, the use of Tetrahydrocannabinol (THC), a cannabinoid compound found
in the cannabis plant, has become more significant both recreationally and medically as a way to
treat pain or nausea, such as morning sickness in expectant mothers. Unfortunately, not much is
known about how the use of these types of substances can affect the gestational development of
the human embryo. Anandamide, a drug similar to THC with its ability to bind to the CB1
receptor in the endocannabinoid system, was used to activate the system and I then observed
changes in embryonic development in zebrafish. Anandamide is a fatty acid neurotransmitter that
has been known to affect many physiological processes such as the peripheral and central
nervous system. Zebrafish embryos were treated with anandamide to be able to observe any
changes during their embryonic development. Zebrafish were an optimal specimen to use
because the receptor found in zebrafish, Cnr1, is similar to the CB1 receptor in the human
endocannabinoid system. By conducting this study, it is possible to apply what we learn to how
the use of cannabinoid compounds in pregnant females could affect the development of their
fetus throughout its gestation process.
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